Stocktoria
BioAtla, Inc. BCAB
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-12-16
BioAtla, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $300,000 | — |
| R&D expense | $43.6M | $63.1M | $103.7M | $79.3M | $58.3M | $19.9M |
| Operating income | -$59.3M | -$73.9M | -$129.7M | -$108.1M | -$96.4M | -$30.1M |
| Interest expense | — | — | — | $0 | $3,000 | $1.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.6M | -$69.8M | -$123.5M | -$106.5M | -$95.4M | -$35.9M |
| EPS (diluted) | $-1.01 | $-1.44 | $-2.58 | $-2.74 | $-2.76 | — |
| Operating cash flow | -$48.2M | -$71.9M | -$104.0M | -$90.4M | -$62.2M | -$36.3M |
| Cash & equivalents | $7.1M | $49.0M | $111.5M | $215.5M | $245.0M | $238.6M |
| Total assets | $13.8M | $52.4M | $119.7M | $225.7M | $254.4M | $244.9M |
| Total liabilities | $50.0M | $38.2M | $49.0M | $45.4M | $43.6M | $35.0M |
| Shareholders' equity | -$36.2M | $14.3M | $70.7M | $180.3M | $210.8M | $210.0M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.